These are the 5 best laptops under $500, recommended by a tech expert
In fact, despite rising global computer costs, you can find a handful of stellar laptops or Chromebooks for under $500 that are designed for work, school, or play. They're ideal for basic tasks, like web browsing and online shopping, reading email, accessing social media, word processing or spreadsheet creation, and some light gaming. If you're a university or college student or taking notes in high school, the prices are also digestible.
We tested a handful of laptops under $500 from Lenovo, Acer, Dell and ASUS, and chose the following five as worthy considerations.These are the 5 best TVs under $500, according to a tech expert
The best headphones of 2025 for every budget, tested by a tech expert
The best robot vacuums and mops we've tested in 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Beeline Holdings Inc (BLNE) Q2 2025 Earnings Call Highlights: Strategic Divestment and Revenue ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Beeline Holdings Inc (NASDAQ:BLNE) successfully divested its spirits assets, allowing a full focus on its core digital mortgage lending business. The company reported a 27% increase in revenue and a 40% decrease in expenses in Q2 2025 compared to Q1 2025. Beeline Holdings Inc (NASDAQ:BLNE) introduced a new equity product that is not tied to interest rates, providing a competitive advantage. The AI sales agent, Bob, significantly improved lead conversion and mortgage application rates, contributing approximately $150,000 in revenue. The company reduced its debt by $6.2 million in 2025, aiming to be debt-free by November 1, 2025, and cash flow positive by January 2026. Negative Points The market remains challenging due to higher interest rates affecting refinance and purchase transactions. The company reported a net loss from continuing operations of $4 million for Q2 2025. There were $500,000 in one-time non-recurring expenses in Q2, impacting financial results. The broader launch of the new equity product has been delayed to ensure proper execution and customer satisfaction. Despite improvements, the company still faces significant scaling challenges and uncertainties in its new product offerings. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with BLNE. Q: Can you provide more details about the home equity cash-out product and the timing of its broader launch? A: (Nick Lauza, CEO) We initially planned to launch in late August or early September but decided to delay to ensure we get it right. The opportunity is massive, with untapped equity in the US market. The Genius Act provides regulatory clarity, and we want to ensure the product is perfect before scaling. We will conduct a select number of transactions over the next 30 to 45 days to gather feedback and ensure consumer interests are prioritized. Q: What are the assumptions behind your profitability projections for late this year or early next year? A: (Nick Lauza, CEO) We are focusing on achieving profitability quickly by cutting $225,000 in monthly recurring expenses, which will be fully realized by September. Our locks are up, and we've reduced our marketing budget by $40,000 monthly while maintaining strong performance. We also had $500,000 in one-time expenses in Q2, which won't recur. We aim to be debt-free by November 1 and cash flow positive by January 2026. Q: Can you explain the economics of the fractional products and the expected volume at scale? A: (Nick Lauza, CEO) Our margins will be higher than our mortgage products, with less work involved since we're underwriting the property, not the consumer. We expect about 33% more revenue per file. Marketing expenses will be minimal as our partner will drive the business. We've identified about 1,000 potential customers who would qualify for this product. Q: What will drive significant growth in 2026, even without rate cuts? A: (Nick Lauza, CEO) We expect strong demand for Beeline Equity, as it provides liquidity based on home equity rather than individual qualifications. This product is ideal for those who can't qualify for cash-out refis or HELOCs. Additionally, our mortgage business is improving, and we have a strong title business team. We anticipate the equity product to be our largest revenue generator in 2026, followed by the mortgage and title businesses. Q: Do you have a sensitivity analysis for how rate cuts could impact growth? A: (Nick Lauza, CEO) While we don't have specific figures, a 25 basis point cut would significantly impact our business as a centralized digital lender. Digital models perform better in low-rate environments, and a 1-point cut would lead to rapid growth. (Chris Moe, CFO) Additionally, the longer rates remain high, the more significant the impact of a cut due to pent-up demand. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Intel's Frankfurt-listed shares rise 3.6% after report US could take stake in chipmaker
LONDON (Reuters) -Intel's Frankfurt-listed shares rose 3.6% on Friday, a day after Bloomberg News reported the Trump administration is in talks with the struggling chipmaker to have the U.S. government potentially take a stake in the company. Intel's U.S. shares surged more than 7% in regular trading Thursday and then another 2.6% after the bell. Intel on Thursday declined to comment on the report. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Android Authority
16 minutes ago
- Android Authority
Blood pressures rise as the FDA cracks down on this wearable's flagship feature
WHOOP TL;DR The FDA has scrutinized Whoop for a new wellness monitoring feature that has not been certified. The FDA considers the Whoop MG (Medical Grade) a medical device and should remove the Blood Pressure Insights feature until approved. Whoop claims the product is not for medical use and will not disable the feature. Wellness wearable maker Whoop, specifically one of its latest fitness bands, has drawn the ire of the FDA after it debuted a feature not approved or certified by the authority. Per a Bloomberg filing, the FDA is pressuring Whoop to disable its Blood Pressure Insights feature. This new app offers its wearers blood pressure estimates and related guidance to provide a holistic view of their well-being. However, the FDA and Whoop can't seem to agree whether the MG's feature constitutes a medical device and must go through the traditional regulatory channels. WHOOP Whoop's marketing material claims that the MG is 'not a medical device and cannot diagnose or manage medical conditions,' and, as a result, the FDA has no authority to 'regulate the product.' However, the FDA seemingly believes otherwise, claiming that potentially erroneous blood pressure readings can harm those wearing the device. Regardless, Whoop reportedly has confirmed that it would not remove the feature, going against the recent trends of health tech firms relenting to the agency. Don't want to miss the best from Android Authority? Set us as a preferred source in Google Search to support us and make sure you never miss our latest exclusive reports, expert analysis, and much more. Medical devices must go through the relevant FDA channels for testing and approval before being marketed and sold; this includes unproven and novel sensors on smartwatches and fitness trackers. While the process ensures consumers are offered clinically-approved products, it can take months, often resulting in features launching well after a device has debuted. The Fitbit Sense's ECG sensor is a particularly memorable example of this. The FDA can demand fines from offending companies or even forbid their products from being sold. Still, the genuine issue appears to be the nebulous definitions of medical devices and modern fitness trackers. We've seen wellness wearable makers debut numerous features in recent years, but blood pressure readings and guidance remain relatively novel. The Samsung Galaxy Watch line and Garmin products like the Index include similar features, but both Korean and American companies have undergone the relevant approval processes before launch. Despite its firm stance, Whoop has reportedly requested an audience with the FDA to clarify the situation, but it's unclear how this tussle will ultimately affect Whoop MG owners. The screenless wellness band debuted for $359 alongside the Whoop 5.0 in May, but the Blood Pressure Insights feature is available only to premium subscribers. Follow
